Prostate Oncology

前列腺肿瘤学

基本信息

批准号：
8300276
负责人：
MAX S. WICHA
金额：
$ 36.67万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-06-01 至 2017-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8300276
关键词：
Age Aging Apoptotic Area Biological Markers Biology Cancer Center Cancer Center Support Grant Cancer Family Cancer Patient Cancer Therapy Evaluation Program Candidate Disease Gene Caring Castration Cell Line Chromosome Mapping Clinic Clinical Clinical Research Clinical Trials Collaborations Commit Correlative Study DNA DNA Methyltransferase DNA Modification Methylases DNA Tumor Viruses Data Department of Defense Detection Development Diagnosis Disease Disease Progression E2F1 gene EZH2 gene Early Diagnosis Environment Epidemiology Epigenetic Process Epithelial Etiology Event Family Funding Gene Expression Genes Genetic Genetic Transcription Genotype Goals Grant Growth Histone Deacetylase Human IL6 gene Individual Infection Inherited Integrins Interleukin-6 Investigation Laboratories Ligands Link Malignant - descriptor Malignant Bone Neoplasm Malignant Neoplasms Malignant neoplasm of prostate Medical Medical Oncologist Metalloproteases Metastatic Neoplasm to the Bone Mission Molecular Morbidity - disease rate National Institute of Diabetes and Digestive and Kidney Diseases Neoplasm Metastasis Oncogenes Outcome Pathway interactions Patients Polyomavirus Predisposition Prevention Prostate Prostate Cancer therapy Prostatic Neoplasms Proteins Proteomics Publications Publishing Quality of life Radiation Oncology Radiosurgery Research Research Personnel Research Support Research Training Resistance Resources Robin bird Role Sampling Scanning Schools Scientist Seeds Seminal Serum Site Solutions Southwest Oncology Group Structure of base of prostate Surveys System Technology Testing Therapeutic Intervention Therapy Clinical Trials Training Transformed Cell Line Translating Translational Research Treatment-Related Cancer Tumor Suppressor Genes United States National Institutes of Health University of Michigan Comprehensive Cancer Center Urologic Cancer Urologic Oncology Urologist Urology Vascular Endothelial Growth Factor Receptor-2 Vorinostat Wood material angiogenesis base bone cancer genetics clinical practice clinically relevant cohort disease diagnosis early onset exome genetic analysis genome wide association study genome-wide linkage improved inhibitor/antagonist meetings member men mortality multidisciplinary new technology novel oncology oncology program outcome forecast programs prospective prostate cancer prevention receptor standard of care survivorship therapy development tool tumor tumor growth tumor progression

项目摘要

The Prostate Oncology Program is an interdisciplinary group of 34 laboratory, translational and clinical researchers from 11 departments and four schools with over $13 million in annual direct research support including nearly $4 million from the NCI. The Prostate Oncology Program, formerly the Urologic Oncology Program, was renamed during this grant period to reflect Its primary mission and critical mass of strength In translating basic and clinical discoveries in prostate cancer into effective medical solutions. The program includes a Prostate SPORE (recently renewed), a PO1 on the Biology of Prostate Cancer Bone Metastasis (recently renewed), a recently renewed Department of Defense funded Prostate Cancer Clinical trials Consortium site (DOD-PCCTC), a prostate-focused Early Disease Research Network (EDRN) site (new this period) and a NIDDK training grant In Clinical and Translational Research Training in Urology (T32). Over this grant period the 34 program members published 563 publications of which 27,9% are intraprogrammatic and 31.3% are Inter-programmatic collaborations. The Program is committed to creating and sustaining a multidisciplinary environment for basic and clinical researchers studying prostate cancer. The scientific aims of the Prostate Oncology Programs are 1) to investigate the genetic and epigenetic events that contribute to malignant transformation in prostate cancer, 2) to characterize aberrations in the tumor microenvironment that facilitate the growth or metastasis of prostate cancer, 3) to translate basic scientific discoveries to develop new biomarkers and therapies in urologic cancers, and 4) to evaluate clinical outcomes with the purpose of guiding therapy development while reducing cancer-related mortality as well as cancer and therapy-associated morbidity. Among the most high Impact research conducted during this grant period were the seminal findings related to the discovery of TMPRSS-ETS fusions in prostate cancer by program members. The objective of the Prostate Oncology Program Is to understand the biology of prostate cancer and to use this information to develop new tools for the detection, diagnosis, prevention, and treatment of prostate cancer.

前列腺肿瘤学计划是来自11个部门的34名实验室，转化和临床研究人员的跨学科小组，其中4所学校拥有超过1300万美元的年度直接研究支持，包括来自NCI的近400万美元。前列腺肿瘤学计划（以前是泌尿外科肿瘤学计划）在此赠款期间被重命名，以反映其主要的任务和关键的力量，以将前列腺癌的基本和临床发现转化为有效的医疗解决方案。该计划包括前列腺孢子（最近更新），关于前列腺癌骨转移生物学的PO1（最近更新），最近更新的国防部资助的前列腺癌临床试验联盟（DOD-PCCTC）是一种以前列腺疾病研究网站（EDRN）的培训（NEW NERTIC and in nur in niDd），（T32）。在这一赠款期间，34个计划成员发布了563个出版物，其中27.9％是磁内图，而31.3％是程序间合作。该计划致力于为研究前列腺癌的基础和临床研究人员创造和维持多学科环境。 The scientific aims of the Prostate Oncology Programs are 1) to investigate the genetic and epigenetic events that contribute to malignant transformation in prostate cancer, 2) to characterize aberrations in the tumor microenvironment that facilitate the growth or metastasis of prostate cancer, 3) to translate basic scientific discoveries to develop new biomarkers and therapies in urologic cancers, and 4) to evaluate clinical outcomes为了指导治疗发展，同时降低了与癌症相关的死亡率以及癌症和治疗相关的发病率。在此赠款期间进行的最高影响研究是与计划成员发现前列腺癌中TMPRSS-ETS融合有关的开创性发现。前列腺肿瘤学计划的目的是了解前列腺癌的生物学，并使用这些信息来开发用于检测，诊断，预防和治疗前列腺癌的新工具。